SciELO - Scientific Electronic Library Online

 
vol.144 issue11Frailty criteria among older people living in the community: An updateInformed consent in clinical practice: persistent doubts author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

RODRIGUEZ, Rocío et al. Understanding current therapies in metastatic melanoma. Rev. méd. Chile [online]. 2016, vol.144, n.11, pp.1448-1458. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872016001100011.

Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.

Keywords : CTLA-4 Antigen; Melanoma; Molecular Targeted Therapy; Pembrolizumab; Programmed Cell Death 1 Receptor.

        · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License